Publications

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

 54
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

Tags:

Previous Article

Blood test can to identify cancer in patients with non-specific symptoms

Next Article

New drug candidate reverses metabolic liver disease and fibrosis

Related Posts

Neural xenografts contribute to long-term recovery in stroke via molecular graft-host crosstalk

Neural xenografts contribute to long-term recovery in s...

 58

Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape

Brain tumors induce widespread disruption of calvarial ...

 45

Allosteric antibodies: a novel paradigm in drug discovery

Allosteric antibodies: a novel paradigm in drug discovery

 110